Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
CSL Behring
CSL Behring
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
N4 Pharma and SRI to target and treat previously unreachable human cells
The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Therapeutic: garadacimab for hereditary angioedema
Hereditary angioedema (HAE) is a rare genetic condition that can be life-threatening
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Latest EU drug approvals span range of health issues
Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
CSL Behring expands operations to Russia
Moscow opening reinforces CSL Behring's promise to deliver therapies to patients with rare and serious diseases worldwide
Regulatory
Bleeding prevention – fibrinogen concentrate
Clinical trials are looking at the potential of fibrinogen, or Factor I, to cut the need for blood transfusions during surgery
Subscribe now